Immunotherapy and Targeted Therapy Flashcards
6 cards from real Mesothelioma Therapy practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 6 Immunotherapy and Targeted Therapy flashcards as text
Which immunotherapy regimen received FDA approval for first-line treatment of unresectable pleural mesothelioma?
Answer: Nivolumab + ipilimumab
Nivolumab + ipilimumab (CheckMate 743) received FDA approval in 2020 as first-line treatment for unresectable pleural mesothelioma.
Nivolumab is classified as which type of immunotherapy?
Answer: PD-1 checkpoint inhibitor
Nivolumab is a PD-1 checkpoint inhibitor that blocks the PD-1 receptor on T cells, restoring their ability to attack cancer cells.
Ipilimumab targets which immune checkpoint?
Answer: CTLA-4
Ipilimumab is a CTLA-4 inhibitor that blocks this immune checkpoint, enhancing T-cell activation and anti-tumor immune responses.
In the CheckMate 743 trial, nivolumab + ipilimumab showed the greatest benefit in which mesothelioma subgroup?
Answer: Non-epithelioid (sarcomatoid/biphasic) cell type
Non-epithelioid mesothelioma (sarcomatoid/biphasic types) showed the greatest benefit from nivolumab + ipilimumab compared to chemotherapy in CheckMate 743.
What is a common immune-related adverse event (irAE) associated with checkpoint inhibitors in mesothelioma?
Answer: Colitis, pneumonitis, hepatitis, and endocrinopathies
Checkpoint inhibitors commonly cause immune-related adverse events including colitis, pneumonitis, hepatitis, and endocrinopathies due to T-cell overactivation.
High-dose corticosteroids are used to treat severe immune-related adverse events (irAEs) from checkpoint inhibitors. Why?
Answer: To suppress the overactive immune response causing organ damage
High-dose corticosteroids suppress the T-cell mediated immune overactivation responsible for tissue damage in severe irAEs.